Patent Expiration of Rilutek to Cause Negative Growth in Amyotrophic Lateral Sclerosis Treatment Market by 2018

Patent Expiration of Rilutek to Cause Negative Growth in Amyotrophic Lateral Sclerosis Treatment Market by 2018 is a new market research publication announced by Reportstack. The amyotrophic lateral sclerosis (ALS) treatment market value will decline from $64 million in 2013 to $38 million by 2018, at a negative Compound Annual Growth Rate (CAGR) of 10.05%.

The company’s latest report states that the largest factor in this decline, which will occur over seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan), will be the patent expiration of Rilutek (riluzole), the only approved therapy for ALS.

As a consequence, it forecasts that the ALS treatment market in the US is set to suffer a substantial reduction in sales over the forecast period, from $38 million in 2013 to $16 million by 2020, at a negative CAGR of 16.10%.

http://www.whatech.com/members-news/reports-industrial/23749-patent-expiration-of-rilutek-to-cause-negative-growth-in-amyotrophic-lateral-sclerosis-treatment-market-by-2018